
Please try another search
The news just keeps getting worse for Aurora Cannabis (NYSE:ACB) (TSX:ACB).
The Canadian marijuana grower posted its results last Thursday after the close. The release showed one of the worst quarters for the Edmonton, Alberta-based company, sending its stock to its lowest level in 2021, hitting $6.70.
Shares have rebounded a bit since then, trading yesterday up just over 2% on the day to close at $7.02. If there was one positive to be found, the pot stock is doing better than it did in October, when it tumbled to about $4. But that's not saying much.
What is speaking volumes is the chorus of analysts who are openly beginning to question what the cannabis grower should do moving forward.
In a note last week, an analyst with Cantor Fitzgerald reportedly raised the question about whether Aurora should get out of the recreational market entirely to focus its attention on the medical marijuana market, a sector where it put in its best performance in a dismal quarter.
Overall, Aurora posted revenues of C$55.1 million (US$66.3 million) in its third quarter that ended Mar. 31. This figure represents a 20.8% drop compared with the same period in the previous year. Analysts consensus were calling for revenues in the $68-million range. And aside from falling well short of expectations, the numbers offered the dubious distinction providing the company its worst showing in six quarters.
Canaccord Genuity downgraded the stock last Friday, moving it from a ‘hold’ to ‘sell,’ while Cantor Fitzgerald kept its ‘neutral’ rating but lowered its target price.
The bright spot remains the company’s performance in the medical marijuana sector, where CEO Miguel Martin said:
“…we delivered the strongest performance in domestic medical and the best results in international medical cannabis of any Canadian LP during the period.”
This prompted Cowen analyst Vivien Azer to underline Aurora’s need to keep its emphasis on the medical sector on a more global footing.
But carving out bright spots might not be what investors are in the mood to do. Just over a year ago, Aurora stock was trading at slightly over $90 just before it fell off a cliff.
The stock is down just under 39% in the last year.
If all goes according to plan, two Canadian-based pot companies will soon be trading their US stock on the NASDAQ exchange.
Aurora Cannabis made the announcement when it unveiled its latest quarterly results last week, explaining it would move its US stock from the New York Exchange to the NASDAQ after the close on May 24. It will continue to use the ticker ACB.
"NASDAQ represents a good fit for Aurora and this listing transfer will enable us to realize cost efficiencies as part of our efforts to deliver long-term value to shareholders," said the Aurora CEO.
Meanwhile, Calgary-based High Tide (OTC:HITIF) is looking to move to the NASDAQ upon approval later this month to reduce its costs. It had previously consolidated all of its issued and outstanding common shares on a 15-to-1 ratio to meet the minimum share price set by NASDAQ.
With the majority of mega-cap earnings results already released, this upcoming week's reports will focus mostly on retailers and their forecasts for the second half of this year...
Stocks on Wall Street rallied on Friday to cap off another brutal week, with the benchmark S&P 500 suffering its longest weekly losing streak since 2011 amid ongoing worries...
These Are The Stocks The Analysts Are Most Interested InWhen it comes to investing, following the money is always a good bet. As good as a company is, as undervalued as it may be,...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.